Navigation Links
Alseres Pharmaceuticals, Inc. Complies with NASDAQ Rule Regarding Recently Filed 10-K
Date:3/31/2009

vements discussed in or implied by the forward-looking statements contained herein. Alseres is providing the information in this press release as of this date and assumes no obligations to update the information in this press release.

Alseres, Cethrin and Altropane are registered trademarks of Alseres Pharmaceuticals, Inc.

http://www.alseres.com/

    Contact:
    Kenneth L. Rice 508-497-2360 x226
    Alseres Pharmaceuticals, Inc.
    krice@alseres.com


'/>"/>
SOURCE Alseres Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Alseres Pharmaceuticals, Inc. Announces $1 Million Financing
2. Alseres Pharmaceuticals, Inc. Reports Third Quarter 2008 Operational and Financial Results
3. Alseres Pharmaceuticals, Inc. Raises $5 Million
4. Alseres Pharmaceuticals, Inc. Reports 2007 Financial Results and Provides Company Highlights
5. Alseres Pharmaceuticals to Host 2007 Financial Results Conference Call
6. Alseres Pharmaceuticals Presents Inosine and Dopamine Transporter (DAT) Blocker Preclinical Data at the American Society for Experimental NeuroTherapeutics (ASENT) Conference
7. Alseres Pharmaceuticals, Inc. to Present at Windhovers Therapeutic Area Partnerships Conference
8. Alseres Pharmaceuticals, Inc. to Present at Bio Investor Forum 2007 Annual Meeting
9. Angiotech Pharmaceuticals, Inc. announces License Agreement with Baxter International Inc.
10. Trubion Pharmaceuticals, Inc. Announces Initiation of Phase 1 Study of SBI-087 for the Treatment of Systemic Lupus Erythematosus (SLE)
11. ADVENTRX Pharmaceuticals, Inc. Reports Fourth Quarter and Full Year 2008 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2015)... ... July 29, 2015 , ... Asymmetrex, LLC ... progress in evaluating the full range of capabilities of its unique cache of ... cells perform the day-to-day renewal and repair of normal tissues and organs. This ...
(Date:7/28/2015)... ... 29, 2015 , ... The new Xsample 530 sample changer for vials can be ... liquid viscosities – from less than 12,000 mPas (internal air) up to 36,000 (external air) ... immediately catches the eye about Xsample 530 is its removable magazine, which is easily lifted ...
(Date:7/28/2015)... ... 28, 2015 , ... In terms of value, aluminium hydroxide ... volume reached close to 1.84 million tonnes in the same year. As of ... the region’s total aluminium hydroxide production; the country’s aluminium hydroxide production posted a ...
(Date:7/28/2015)... -- Deerfield Management Company, L.P. today announced the launch ... invest in groundbreaking advancements in science that may lead ... diseases. The venture capital fund will also back new ... improve the way healthcare is delivered to patients. ... funds in the sector, will donate all profits not ...
Breaking Biology Technology:Asymmetrex Plans to Report Results From Adult Stem Cell Technology Development Milestone Studies At End of Summer 2Asymmetrex Plans to Report Results From Adult Stem Cell Technology Development Milestone Studies At End of Summer 3Asymmetrex Plans to Report Results From Adult Stem Cell Technology Development Milestone Studies At End of Summer 4New Moves in Automatic Sample Handling: Introducing Xsample 530 2EU27 Aluminium Hydroxide Market Analysed and Forecast by BAC Reports in New Research Study Available at MarketPublishers.com 2EU27 Aluminium Hydroxide Market Analysed and Forecast by BAC Reports in New Research Study Available at MarketPublishers.com 3Deerfield Launches $550 Million Healthcare Venture-Capital Fund 2Deerfield Launches $550 Million Healthcare Venture-Capital Fund 3
... LAIYANG, China, Feb. 17 /PRNewswire-Asia-FirstCall/ -- Genesis,Pharmaceuticals Enterprises, Inc. ... pharmaceutical company with its principal operations in the,People,s Republic ... quarter of its fiscal year 2009 ended December 31, ... Fiscal Year 2009 Highlights, -- Revenue ...
... in the Biotech IndustryFT. LAUDERDALE, Fla., Feb. ... full-service securities broker-dealer and investment bank, is ... Newbridge BioVentures Division ("NBV"). NBV is dedicated ... biotech industry and related investment opportunities for ...
... 17 Human Genome Sciences, Inc. (Nasdaq: ... GSK ) has initiated a Phase 3 clinical trial ... Syncria (R) (albiglutide) in the long-term treatment of ... will receive a $9 million milestone payment in the ...
Cached Biology Technology:Genesis Pharmaceuticals Reports Results for the Second Quarter of its Fiscal Year 2009 2Genesis Pharmaceuticals Reports Results for the Second Quarter of its Fiscal Year 2009 3Genesis Pharmaceuticals Reports Results for the Second Quarter of its Fiscal Year 2009 4Genesis Pharmaceuticals Reports Results for the Second Quarter of its Fiscal Year 2009 5Genesis Pharmaceuticals Reports Results for the Second Quarter of its Fiscal Year 2009 6Genesis Pharmaceuticals Reports Results for the Second Quarter of its Fiscal Year 2009 7Genesis Pharmaceuticals Reports Results for the Second Quarter of its Fiscal Year 2009 8Genesis Pharmaceuticals Reports Results for the Second Quarter of its Fiscal Year 2009 9Genesis Pharmaceuticals Reports Results for the Second Quarter of its Fiscal Year 2009 10Genesis Pharmaceuticals Reports Results for the Second Quarter of its Fiscal Year 2009 11Genesis Pharmaceuticals Reports Results for the Second Quarter of its Fiscal Year 2009 12Genesis Pharmaceuticals Reports Results for the Second Quarter of its Fiscal Year 2009 13Genesis Pharmaceuticals Reports Results for the Second Quarter of its Fiscal Year 2009 14Genesis Pharmaceuticals Reports Results for the Second Quarter of its Fiscal Year 2009 15Genesis Pharmaceuticals Reports Results for the Second Quarter of its Fiscal Year 2009 16Newbridge Securities Corporation Forms BioVentures Division 2Human Genome Sciences to Receive $9 Million Milestone Payment Related to GlaxoSmithKline Initiation of Phase 3 Clinical Trial of Syncria(R) in Type 2 Diabetes 2Human Genome Sciences to Receive $9 Million Milestone Payment Related to GlaxoSmithKline Initiation of Phase 3 Clinical Trial of Syncria(R) in Type 2 Diabetes 3Human Genome Sciences to Receive $9 Million Milestone Payment Related to GlaxoSmithKline Initiation of Phase 3 Clinical Trial of Syncria(R) in Type 2 Diabetes 4
(Date:6/30/2015)... , June 30, 2015 To bolster its ... provider HYPR Corp. announced today the addition of two new ... serve as board advisor and David Raviv will ... team underscore HYPR Corp.,s commitment to providing the most secure ... Dimitri Sirota co-founded Layer 7 Technologies, a provider of ...
(Date:6/26/2015)... 2015 ATL Technology, LLC, a top provider of ... single use solutions, headquartered in Springville, Utah ... California corporation with locations in ... Costa Rica ). This acquisition will incorporate ... with ATL Technology,s existing facility in Costa Rica ...
(Date:6/25/2015)... -- TAKE Solutions Ltd., a global business technology solutions provider, ... and Trademark Office (USPTO) for its "Method for Optimizing ... Accelerators to reduce the time taken to standardize trial ... the accelerators), thus reducing time to market. ... heart of the patented Clinical Data Standardization Process are ...
Breaking Biology News(10 mins):HYPR Corp. Expands Biometric Authentication Team with Enterprise All Stars 2HYPR Corp. Expands Biometric Authentication Team with Enterprise All Stars 3ATL Technology Announces Acquisition of MedConx, Inc. and Expanded Global Footprint 2TAKE Solutions Awarded Patent By USPTO 2
... overweight and obese adults, a diet rich in slowly ... high-fiber foods, significantly reduces markers of inflammation associated with ... Hutchinson Cancer Research Center. Such a "low-glycemic-load" diet, which ... a hormone that helps regulate the metabolism of fat ...
... like protein, is highly elevated in a variety of ... contributes to tumorigenic phenotypes remains unclear and is the ... issue of Experimental Biology and Medicine . ... State University School of Medicine in New Orleans, the ...
... National Institute of Standards and Technology (NIST), in collaboration ... has developed two new Standard Reference Materials (SRMs) for ... a sort of chemical ruler to check the accuracy ... replace and improve older versions, adding measures for emerging ...
Cached Biology News:A diet rich in slowly digested carbs reduces markers of inflammation in overweight and obese adults 2ISG15: A novel therapeutic target to slow breast cancer cell motility 2NIST releases 2 new SRMs for monitoring human exposure to environmental toxins 2
Donor Goat Serum...
The Varian 4000 GC/MS system offers three easily switchable ionization configurations: internal ionization (II), external ionization (EI) or hybrid chemical ionization (CI)...
GeneRacer is an advanced RACE (rapid amplification of cDNA ends) technique that improves the efficiency of amplifying full-length 5' and 3' cDNA ends. With the GeneRacer Kit you can:...
One-step, microplate or cuvet, colorimetric, detection range 0.04% to 4%. Procedure: 30 min....
Biology Products: